Presentation and management of choriocarcinoma after nonmolar pregnancy. 1995

J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
Department of Medical Oncology, Charing Cross Hospital, London, UK.

OBJECTIVE To ascertain the mode of presentation and treatment outcome for women with choriocarcinoma after a nonmolar pregnancy. METHODS Retrospective analysis of case records between 1985 and 1994. METHODS A referral centre for trophoblastic disease. METHODS One hundred women with choriocarcinoma: 62 after a live birth, six after a live birth preceded by a molar pregnancy and 32 after a nonmolar abortion. RESULTS Choriocarcinoma after nonmolar pregnancies represent 17% of the total gestational trophoblastic tumours requiring treatment. Vaginal bleeding was the commonest symptom in all groups, but symptoms from metastatic disease were important in the group presenting after a live birth. Metastatic disease was present in 31% of cases after live birth and 43% post-abortion. The median interval between the antecedent pregnancy and choriocarcinoma was five and six months, respectively. High risk multi-agent chemotherapy was required in 82% and 60% of cases, respectively. The mortality rate was significantly higher after a live birth than a nonmolar abortion (21% vs 6%). CONCLUSIONS Treatment of choriocarcinoma after a live birth is associated with an unacceptably high mortality rate. Vaginal bleeding is an important early symptom and a pregnancy test should be performed if it persists after usual medical treatment.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011256 Pregnancy Outcome Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO. Outcome, Pregnancy,Outcomes, Pregnancy,Pregnancy Outcomes
D002822 Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL). Choriocarcinomas
D005260 Female Females
D006063 Chorionic Gonadotropin A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN). Chorionic Gonadotropin, Human,HCG (Human Chorionic Gonadotropin),Biogonadil,Choriogonadotropin,Choriogonin,Chorulon,Gonabion,Human Chorionic Gonadotropin,Pregnyl,Gonadotropin, Chorionic,Gonadotropin, Human Chorionic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006828 Hydatidiform Mole Trophoblastic hyperplasia associated with normal gestation, or molar pregnancy. It is characterized by the swelling of the CHORIONIC VILLI and elevated human CHORIONIC GONADOTROPIN. Hydatidiform moles or molar pregnancy may be categorized as complete or partial based on their gross morphology, histopathology, and karyotype. Molar Pregnancy,Pregnancy, Molar,Hydatid Mole,Hydatidiform Mole, Complete,Hydatidiform Mole, Partial,Complete Hydatidiform Mole,Complete Hydatidiform Moles,Hydatid Moles,Hydatidiform Moles,Hydatidiform Moles, Complete,Hydatidiform Moles, Partial,Molar Pregnancies,Mole, Complete Hydatidiform,Mole, Hydatid,Mole, Hydatidiform,Mole, Partial Hydatidiform,Moles, Complete Hydatidiform,Moles, Hydatid,Moles, Hydatidiform,Moles, Partial Hydatidiform,Partial Hydatidiform Mole,Partial Hydatidiform Moles,Pregnancies, Molar
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
October 2006, The Journal of reproductive medicine,
J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
January 1983, Patologia polska,
J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
March 1999, British journal of cancer,
J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
January 1994, Acta oncologica (Stockholm, Sweden),
J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
January 2010, The Journal of reproductive medicine,
J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
April 2012, Journal of obstetrics and gynaecology of India,
J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
January 1964, Bulletin de la Federation des societes de gynecologie et dobstetrique de langue francaise,
J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
May 1987, The Australian & New Zealand journal of obstetrics & gynaecology,
J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
July 1956, American journal of obstetrics and gynecology,
J A Tidy, and G J Rustin, and E S Newlands, and M Foskett, and S Fuller, and D Short, and P Rowden
April 2003, World journal of surgical oncology,
Copied contents to your clipboard!